These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 1879096)

  • 61. Oral and intravenous pharmacokinetics of milrinone in human volunteers.
    Stroshane RM; Koss RF; Biddlecome CE; Luczkowec C; Edelson J
    J Pharm Sci; 1984 Oct; 73(10):1438-41. PubMed ID: 6502494
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Influence of genetic polymorphism on the metabolism and disposition of encainide in man.
    Wang T; Roden DM; Wolfenden HT; Woosley RL; Wood AJ; Wilkinson GR
    J Pharmacol Exp Ther; 1984 Mar; 228(3):605-11. PubMed ID: 6423808
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis.
    Wiegers U; Hanrath P; Kuck KH; Pottage A; Graffner C; Augustin J; Runge M
    Eur J Clin Pharmacol; 1983; 24(4):503-7. PubMed ID: 6407848
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Elimination kinetics of captopril in patients with renal failure.
    Duchin KL; Pierides AM; Heald A; Singhvi SM; Rommel AJ
    Kidney Int; 1984 Jun; 25(6):942-7. PubMed ID: 6381858
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Guanadrel sulfate: a postganglionic sympathetic inhibitor for the treatment of mild to moderate hypertension.
    Palmer JD; Nugent CA
    Pharmacotherapy; 1983; 3(4):220-9. PubMed ID: 6351026
    [No Abstract]   [Full Text] [Related]  

  • 67. The influence of urinary pH on flecainide excretion and its serum pharmacokinetics.
    Muhiddin KA; Johnston A; Turner P
    Br J Clin Pharmacol; 1984 Apr; 17(4):447-51. PubMed ID: 6326790
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Enalapril maleate and a lysine analogue (MK-521): disposition in man.
    Ulm EH; Hichens M; Gomez HJ; Till AE; Hand E; Vassil TC; Biollaz J; Brunner HR; Schelling JL
    Br J Clin Pharmacol; 1982 Sep; 14(3):357-62. PubMed ID: 6289858
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Kinetics of fenoximone, a new cardiotonic, in healthy subjects.
    Alken RG; Belz GG; Haegele KD; Meinicke T; Schechter PJ
    Clin Pharmacol Ther; 1984 Aug; 36(2):209-16. PubMed ID: 6235081
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biotransformation and elimination of 14C-flecainide acetate in humans.
    McQuinn RL; Quarfoth GJ; Johnson JD; Banitt EH; Pathre SV; Chang SF; Ober RE; Conard GJ
    Drug Metab Dispos; 1984; 12(4):414-20. PubMed ID: 6148206
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.
    Ishizaki T; Ohnishi A; Sasaki T; Kushida K; Horai Y; Chiba K; Suganuma T
    Eur J Clin Pharmacol; 1983; 25(1):95-101. PubMed ID: 6137389
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Biotransformation of urapidil: metabolites in serum and urine and their biological activity in vitro and in vivo.
    Zech K; Eltze M; Kilian U; Sanders KH; Kolassa N
    Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):180-96. PubMed ID: 6098228
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects.
    Witte PU; Irmisch R; Hajdú P; Metzger H
    Eur J Clin Pharmacol; 1984; 27(5):577-81. PubMed ID: 6097458
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetics of carteolol in relation to renal function.
    Hasenfuss G; Schäfer-Korting M; Knauf H; Mutschler E; Just H
    Eur J Clin Pharmacol; 1985; 29(4):461-5. PubMed ID: 4092726
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Terazosin kinetics after oral and intravenous doses.
    Patterson SE
    Clin Pharmacol Ther; 1985 Oct; 38(4):423-7. PubMed ID: 4042526
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Haemodialysis does not affect the pharmacokinetics of nifedipine.
    Martre H; Sari R; Taburet AM; Jacobs C; Singlas E
    Br J Clin Pharmacol; 1985 Aug; 20(2):155-8. PubMed ID: 4041333
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Felodipine kinetics in healthy men.
    Edgar B; Regårdh CG; Johnsson G; Johansson L; Lundborg P; Löfberg I; Rönn O
    Clin Pharmacol Ther; 1985 Aug; 38(2):205-11. PubMed ID: 4017422
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage.
    Rämsch KD; Ahr G; Tettenborn D; Auer LM
    Neurochirurgia (Stuttg); 1985 May; 28 Suppl 1():74-8. PubMed ID: 4010869
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetics of cibenzoline in patients with renal impairment.
    Canal M; Flouvat B; Aubert P; Guedon J; Prinseau J; Baglin A
    J Clin Pharmacol; 1985 Apr; 25(3):197-203. PubMed ID: 3998200
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.
    Kleinbloesem CH; van Brummelen P; van Harten J; Danhof M; Breimer DD
    Clin Pharmacol Ther; 1985 May; 37(5):563-74. PubMed ID: 3987180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.